Analysts Set BioLife Solutions, Inc. (NASDAQ:BLFS) Price Target at $23.67

BioLife Solutions, Inc. (NASDAQ:BLFS) has been given a consensus rating of “Buy” by the five research firms that are currently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $23.67.

Several brokerages have recently weighed in on BLFS. StockNews.com upgraded BioLife Solutions to a “sell” rating in a report on Friday, May 10th. Benchmark upgraded BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Monday, May 13th. Finally, Jefferies Financial Group began coverage on BioLife Solutions in a report on Thursday, April 4th. They issued a “buy” rating and a $22.00 price objective for the company.

Insider Buying and Selling

In related news, insider Sarah Aebersold sold 3,000 shares of BioLife Solutions stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $21.03, for a total transaction of $63,090.00. Following the completion of the transaction, the insider now owns 61,683 shares in the company, valued at $1,297,193.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CMO Todd Berard sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $20.18, for a total transaction of $201,800.00. Following the completion of the sale, the chief marketing officer now owns 108,894 shares in the company, valued at $2,197,480.92. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sarah Aebersold sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $21.03, for a total value of $63,090.00. Following the sale, the insider now owns 61,683 shares of the company’s stock, valued at approximately $1,297,193.49. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,845 shares of company stock worth $510,734. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently made changes to their positions in the company. Conestoga Capital Advisors LLC boosted its holdings in shares of BioLife Solutions by 1.0% during the first quarter. Conestoga Capital Advisors LLC now owns 65,477 shares of the medical equipment provider’s stock worth $1,215,000 after acquiring an additional 630 shares during the period. Sei Investments Co. raised its position in shares of BioLife Solutions by 1.4% in the first quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider’s stock valued at $1,117,000 after buying an additional 839 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of BioLife Solutions by 167.2% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 1,020 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of BioLife Solutions by 10.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock valued at $281,000 after buying an additional 1,374 shares in the last quarter. Finally, Texas Permanent School Fund Corp raised its position in shares of BioLife Solutions by 4.7% in the first quarter. Texas Permanent School Fund Corp now owns 31,145 shares of the medical equipment provider’s stock valued at $578,000 after buying an additional 1,384 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Performance

BLFS opened at $20.45 on Tuesday. The business’s 50-day moving average price is $20.61 and its two-hundred day moving average price is $18.46. BioLife Solutions has a 1 year low of $8.92 and a 1 year high of $23.85. The company has a market capitalization of $942.11 million, a price-to-earnings ratio of -14.40 and a beta of 1.85. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.06. BioLife Solutions had a negative return on equity of 12.89% and a negative net margin of 45.84%. The firm had revenue of $31.73 million for the quarter, compared to the consensus estimate of $29.30 million. During the same quarter last year, the business posted ($0.27) EPS. Equities analysts expect that BioLife Solutions will post -0.44 EPS for the current fiscal year.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.